Jason is an Investment Associate of NVM.
Jason, who will be working from NVM’s Reading office, has spent his early career as a software engineer in the financial sector. After completing the graduate scheme at Morgan Stanley, Jason joined the securitised products development team where he built data and analytic tools for strategists and traders. Following this, he worked as a quantitative developer for a systematic hedge fund, acting as the lead developer on the rewrite of the trade generation system and working closely with the research team to implement trading algorithms.
Prior to this, Jason completed both an undergraduate and a Master’s degree in Mathematics and Computer Science at the University of Oxford, graduating with a First Class Honours and winning the Worcester College Society Award for Science Subjects.
Jason represents NVM on the board of Ablatus Therapeutics Limited. He has also been involved in a number of transactions, including NVM’s investment in Newcells Biotech and Clarilis.